TCS, Sun Pharma and other stocks that moved most on March 9

Equity benchmark BSE Sensex opened the session in green and further climbed 1,469.64 points or 2.75% to 54,893.73 during the day. It finally closed 1,223.24 points or 2.29% higher at 54,647.33. Similarly, the broader NSE Nifty climbed 331.90 points or 2.07% to close at 16,345.35.

Among sectoral indices, except metal, all other sectors ended in green including capital goods, auto and realty indices were up 2-3%. BSE midcap and smallcap surged 2% each.

Also Read | Closing Bell: Sensex jumps 1,223 points, Nifty closes at 16,345

Here are the key stocks that moved most during today’s trading session:

Tata Consultancy Services: The share closed 1.13% higher at Rs 3,640.70 after the IT major launched its Rs 18,000 crore share buyback offer that will close on March 23. This comes after Tata Sons bought Air India from the government for an equal amount. The company will pay Rs 2,700 crore to the government and the remaining amount will go to paying the debt.

Also Read | LIC gets SEBI’s nod for the biggest Indian IPO ever

Bajaj Electricals: The share closed 4.83% down at Rs 1,057.40% after Morgan Stanley downgraded its rating on the stock to ‘equal-weight’ from ‘overweight’ and cut its target price to Rs 1,223 from Rs 1,340.

Also Read | Oil prices continue to rise as US bans Russian imports

Sun Pharmaceuticals: The stock closed 1.29% down at Rs 866.00 after the company announced that it has completed the acquisition of Galderma companies in Delaware, Japan and Canada. It has acquired the companies for USD 99.279 million after taking into account the working capital adjustments, the company said in a regulatory filing.

Also Read | Vikram Limaye ‘not interested’ in applying for second term as NSE CEO & MD

TVS Motors: The share closed 4.13% higher at Rs 557.25. A meeting of the board of directors of TVS Motor company has been called on March 18, 2022, to consider and declare the interim dividend if any, to stakeholders of the company for the year ending March 31, 2022, the company said in a statement.

Also Read | US crypto exchange CoinZoom to suspend new accounts within Russia: Report

Zydus Lifesciences: The share surged 4.19% to close at Rs 358.95 after the company’s US subsidiary Sentynl Therapeutics Inc acquired global rights for the development and commercialisation of BridgeBio Pharma’s Nulibry drug.